Nautilus Biotechnology (NAUT) Upgraded to Buy: Here's What You Should Know
Nautilus Biotechnology, Inc. (NAUT) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q1 2024 Earnings Call Transcript
Q1 2024 Earnings Call April 30, 2024 Nautilus Biotechnology, Inc. beats earnings expectations. Reported EPS is $-0.00015, expectations were $-0.16. NAUT isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).
The 2024 Lincoln Nautilus is a premium SUV with impressive features and new design language. Available in multiple trims, ...
Patek Philippe was obviously going to great lengths to avoid the Royal Oak problem. But I’ve come to understand that Patek ...
Then-FSU President Sandy D'Alemberte was dismayed by the crazy quilt construction and worried Bucher could not afford the ...
Frank Fogarty knew nothing about nuclear physics on ships when he got pulled from his Korean War submarine duty to interview ...
12don MSN
Darien officials oppose 'deeply concerning' Stamford cannabis dispensary location near a border between the two ...
A new outdoor attraction — the first of its kind in the U.S — is expected to come to Virginia Beach sometime this summer.
The Nautilus Observation Tower, located behind the Virginia Aquarium, will be open to visitors by mid-summer, according to ...
Lincoln Nautilus garners praise for its reimagined interior and innovative digital experience, securing a spot in Wards 10 ...
Don’t miss the Michelin-starred, two-day-only Six Hands dinner and two bar takeovers at Four Seasons Hotel Jakarta this May 2024.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback